Viela Bio targets CD40 antibodies domestically declared clinically.

On March 7, 2020, the clinical application of vib4920, the second drug under study of viela bio, was accepted by nmpa.vib4920 is an antibody like drug targeting CD40, which is made of Tn3 scaffold fusion protein that specifically binds to CD40.vib4920 is a CD40 antagonist for the treatment of autoimmune diseases.viela bio was split from MedImmune on February 28, 2018. When it was established, viela bio received US $250 million round a financing. A consortium composed of Tonghe Yucheng, Boyu capital and Hillhead capital led this round of investment, and Temasek and SIRONA capital participated in the investment.AstraZeneca is the largest minority shareholder of the company.viela bio is committed to developing new mechanisms of autoimmune drugs to meet clinical needs.the drugs under study include inebilizumab targeting CD19, vib4920 targeting CD40 and vib7734 targeting ilt7.viela bio's self immunity solution is very clear: inebilizumab solves the problem of B cells; vib4920 solves the interaction between T cells and B cells, dendritic cells and macrophages through CD40-CD40L pathway; vib7734 solves the problem of pDCs.vib4920 is an antibody like structure in design, and Tn3 is an antibody like structure derived from FN3 (fibronectin type III).the fusion of CD40 specific Tn3 into albumin can avoid thromboembolism side effects (no platelet aggregation) caused by antibody FC.in recent years, antibody like structures have developed rapidly. Affibody, bicycle peptides, DARPins, FN3, etc. have entered the vision of large pharmaceutical enterprises, and have completed the layout.vib4920 showed a good dose-dependent effect in stage 1B (C-reactive protein in the figure below), which reduced the production of autoantibodies and disease activity.Tn3 is only 10kDa in size and can be expressed in E.coli. The expression level is generally about 40-400mg / L.small summary antibody is becoming a new choice to replace antibody drugs. Currently, it is in the stage of rapid transformation. In addition to the advantages of diagnosis, it also has the advantages of antibody drugs in some aspects.viela bio focuses on costimulatory signals to develop self immune drugs, and oncology immunofocus CD24 FC develops self immune drugs. These fields have become a clear stream of hot tumor drugs, and new mechanism self immune drugs may bring more surprises.extended reading challenges and opportunities for non-toxic scaffold drugs (2018); engineered protein scaffolds as next generation therapeutics (2020); A-side of CD24; fibronectin type III domains engineered to bind CD40L: cloning, expression, purification, Crystal and preliminary X-ray diffraction analysis of two complexes (2013); non immunoglobin scaffolds: a focus on their targets (2015); viela bio official website.please contact wechat: wzh910605, business cooperation contact: 18868193180, you are welcome to forward and share. If any other media or website needs to reprint or quote all the copyright content of this website, it must be authorized and marked "transferred from: biopharmaceutical monograph" in an eye-catching position.